[go: up one dir, main page]

WO1996000568A1 - Agent anti-metastatique - Google Patents

Agent anti-metastatique Download PDF

Info

Publication number
WO1996000568A1
WO1996000568A1 PCT/RU1995/000077 RU9500077W WO9600568A1 WO 1996000568 A1 WO1996000568 A1 WO 1996000568A1 RU 9500077 W RU9500077 W RU 9500077W WO 9600568 A1 WO9600568 A1 WO 9600568A1
Authority
WO
WIPO (PCT)
Prior art keywords
metastatic agent
meτasτazοv
treatment
metastatic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU1995/000077
Other languages
English (en)
Russian (ru)
Inventor
Igor Vyacheslavovich Belov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO1996000568A1 publication Critical patent/WO1996000568A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the invention is in medicine, in particular, in clinical practice, and may be used for the treatment of cancer patients.
  • this medium has a deficient asset of 10 mediums.
  • the goal of the invention is to increase specific activity.
  • transplants were implanted internally with a finite of 1 million normal cells in 0.1 ml. surroundings 199 into the left paw of female mice of the C5? ⁇ 1 / 6 line weighing 1.8–20 g.
  • the initial treatment with drugs began with the moment of manifestation of 0 knots.
  • the dose was administered at a dose of 300 mg / kg. ⁇ e ⁇ de ⁇ alin - -1000 mg / ⁇ g, ⁇ - ⁇ i ⁇ z ⁇ l -200 mg / ⁇ g in ⁇ echenie 8 su ⁇ .
  • mice with a Lewis lung cancer the values of these indicators were equal.
  • mice were ⁇ azhennymi leg ⁇ imi vyyav- Lena only single nodes, ⁇ than svide ⁇ els ⁇ v ⁇ val ⁇ ⁇ ez ⁇ e5 (b ⁇ lee than ⁇ yad ⁇ ) reducing the quantities ⁇ i ⁇ e ⁇ iev ⁇ liches ⁇ va me ⁇ as ⁇ az ⁇ v ua ⁇ dn ⁇ zhiv ⁇ n ⁇ e (90 ⁇ l ⁇ schadi me ⁇ as ⁇ az ⁇ v and X (96 X).

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'agent anti-métastatique de l'invention est destiné à être utilisé dans le domaine de la pharmacologie clinique et peut être employé dans le traitement de patients souffrant de maladies malignes. L'objectif de l'invention est d'améliorer l'action spécifique. L'essence et la nouveauté de l'invention résident dans l'utilisation d'une substance connue, la perfluorodécaline, à une nouvelle fin en tant qu'agent anti-métastatique.
PCT/RU1995/000077 1994-06-29 1995-04-26 Agent anti-metastatique Ceased WO1996000568A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU9494024337A RU2088223C1 (ru) 1994-06-29 1994-06-29 Антиметастатическое средство
RU94024337 1994-06-29

Publications (1)

Publication Number Publication Date
WO1996000568A1 true WO1996000568A1 (fr) 1996-01-11

Family

ID=20157843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1995/000077 Ceased WO1996000568A1 (fr) 1994-06-29 1995-04-26 Agent anti-metastatique

Country Status (2)

Country Link
RU (1) RU2088223C1 (fr)
WO (1) WO1996000568A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2422310A (en) * 2004-12-02 2006-07-26 Kaizen Matsumoto Perfluorocarbon solvents for reducing the concentration of carcinogens in cells
WO2015150293A1 (fr) * 2014-04-02 2015-10-08 Zhuwu Zeyi Composition de soin des ongles
WO2016178099A1 (fr) * 2016-01-04 2016-11-10 Mustafa Pehlivan Nano fluoro tricyclohexane

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2162692C1 (ru) * 1999-06-24 2001-02-10 Воробьев Сергей Иванович Состав на основе эмульсии перфторорганических соединений для медико-биологических целей
RU2308096C2 (ru) * 2005-09-27 2007-10-10 Валерий Хажмуратович ЖИЛОВ Способ снижения метастазирования меланомы в-16

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981000002A1 (fr) * 1979-06-25 1981-01-08 Suntech Utilisation de carbone perfluore pour le traitement des brulures
US4289499A (en) * 1978-10-13 1981-09-15 Childrens Hospital Medical Center Selecting perfluorocarbon compounds for synthetic blood
EP0279379A1 (fr) * 1987-02-20 1988-08-24 Air Products And Chemicals, Inc. Administration interstitielle d'emulsions de composés perfluorés pour la reoxygénation de cellules cancéreuses hypoxiques
EP0307087A1 (fr) * 1987-08-05 1989-03-15 Alliance Pharmaceutical Corp. Emulsions d'hydrocarbures fluorés pour l'utilisation "in vivo"
WO1994007475A1 (fr) * 1992-09-30 1994-04-14 Forman B Mervyn Perfusion d'une emulsion de compose au perfluorocarbone effectuee au cours d'une angioplastie transluminale percutanee

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289499A (en) * 1978-10-13 1981-09-15 Childrens Hospital Medical Center Selecting perfluorocarbon compounds for synthetic blood
WO1981000002A1 (fr) * 1979-06-25 1981-01-08 Suntech Utilisation de carbone perfluore pour le traitement des brulures
US4366169A (en) * 1979-06-25 1982-12-28 Sun Tech, Inc. Use of perfluorocarbons as wound treatment
EP0279379A1 (fr) * 1987-02-20 1988-08-24 Air Products And Chemicals, Inc. Administration interstitielle d'emulsions de composés perfluorés pour la reoxygénation de cellules cancéreuses hypoxiques
EP0307087A1 (fr) * 1987-08-05 1989-03-15 Alliance Pharmaceutical Corp. Emulsions d'hydrocarbures fluorés pour l'utilisation "in vivo"
WO1994007475A1 (fr) * 1992-09-30 1994-04-14 Forman B Mervyn Perfusion d'une emulsion de compose au perfluorocarbone effectuee au cours d'une angioplastie transluminale percutanee

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2422310A (en) * 2004-12-02 2006-07-26 Kaizen Matsumoto Perfluorocarbon solvents for reducing the concentration of carcinogens in cells
WO2006059063A3 (fr) * 2004-12-02 2006-12-21 Kaizen Robert Matsumoto Solvants de cancerogenes pour reduction de la concentration de cancerogenes cellulaire
GB2422310B (en) * 2004-12-02 2006-12-27 Kaizen Matsumoto Carcinogen solvents in reducing the carcinogen concentration of cells
WO2015150293A1 (fr) * 2014-04-02 2015-10-08 Zhuwu Zeyi Composition de soin des ongles
WO2016178099A1 (fr) * 2016-01-04 2016-11-10 Mustafa Pehlivan Nano fluoro tricyclohexane

Also Published As

Publication number Publication date
RU94024337A (ru) 1996-05-10
RU2088223C1 (ru) 1997-08-27

Similar Documents

Publication Publication Date Title
Mccarthy et al. A role for 1, 25-dihydroxyvitamin D3 in control of bone-marrow collagen deposition?
Rubio Further studies on the therapeutic effect of indomethacin on esophageal tumors
JP2002513386A (ja) 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法
Smith et al. Ozone therapy: a critical physiological and diverse clinical evaluation with regard to immune modulation, anti-infectious properties, anti-cancer potential, and impact on anti-oxidant enzymes
EP0630644A4 (fr) Compose pharmaceutique anti-microbien et induisant des interferons.
KR102091464B1 (ko) 항염증용 조성물
WO2005039636A1 (fr) Produit pour potentialiser les effets curatifs et intensifier l'action d'un medicament
WO1996000568A1 (fr) Agent anti-metastatique
WO2003072124A1 (fr) Methode d'induction de differentiation cellulaire
Green Aloe vera extracts in equine clinical practice
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
Williams et al. INFLUENCE OF HORMONES UPON PHOSPHATASE CONTENT OF RAT FEMURS I. EFFECTS OFADRENAL CORTICAL SUBSTANCES AND PARATHYROID EXTRACT
WO2005004904A1 (fr) Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
Lis-Balchin et al. A study of the changes in the bioactivity of essential oils used singly and as mixtures in aromatherapy
WO2005004789A2 (fr) Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative ou quantitative de l'adn extracellulaire du sang
EP2920145A1 (fr) Oxiran amines
CN101951932B (zh) 蒌叶叶提取物在制备治疗对氧化应激敏感的人类恶性病药物中的应用
JP2000119126A (ja) 生体内環境快適化組成物
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
Machado et al. Clinical features and successful recovery from disseminated nocardiosis after BMT
EP0402208A1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
KR100355497B1 (ko) 류코트리엔생성저해활성을가지는정유성분
US20220008514A1 (en) Combined use of selective serotonin reuptake inhibitors and hematopoietic growth factors for treating hematopoietic diseases
Regelson et al. The effect of radiation on splenomegaly induced by the friend leukemia virus and its modification by ethyl-N-bis (2, 2-dimethyl-ethylamidinophosphoro)-carbamate (AB-132), actinomycin D, and AET
RU94035977A (ru) Лекарственный сбор для лечения и профилактики аденомы простаты и цистита

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase